Last reviewed · How we verify

NCT05161910: NGAL

ROLE OF URINARY BIOMARKER NEUTROPHIL GELATINASE ASSOCIATED LIPOCALCIN (NGAL) IN EARLY PREDICTION OF AKI IN CIRRHOSIS OF LIVER

Completed Last updated 29 December 2021
What this trial tests

trial testing Biomarkers in Renal Failure in 120 participants. Completed in 30 August 2021.

Timeline
1 March 2020
Primary endpoint
1 February 2021
30 August 2021

Quick facts

Lead sponsorAsian Institute of Gastroenterology, India
StatusCompleted
Study typeOBSERVATIONAL
Enrollment120
Start date1 March 2020
Primary completion1 February 2021
Estimated completion30 August 2021
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Asian Institute of Gastroenterology, India

Who can join

Adults 18 to 75, any sex, with Renal Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Kidney dysfunction is a complex and common event in patients with liver cirrhosis. Although novel treatments have shown some promising results , acute kidney injury remains a major complication of decompensated liver cirrhosis with high morbidity and mortality rates . AKI occurs in up to 19-20% of hospitalized patients with liver cirrhosis and among the most frequent causes are prerenal azotemia (PRA), hepatorenal syndrome and acute tubular necrosis , with prevalence rates estimated around 68%, 25%, and 33%, respectively. The introduction and widespread use of diagnostic criteria of AKI in the area of cirrhosis has contributed to an increased awareness and earlier detection of AKI. However, some important problems remain. One of the main issues is the differential diagnosis of AKI, particularly between acute tubular necrosis (ATN) and hepatorenal syndrome (HRS-AKI). This is important because treatment is different; renal replacement therapy (RRT) is used for the former, and vasoconstrictors and albumin are used for the latter.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Biomarkers

Trials testing the same drug.

Other recruiting trials for Renal Failure

Currently open trials in the same condition.

Other Asian Institute of Gastroenterology, India trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05161910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing